Udeani George, Evans John, Cole Phillip, Friedland H David
CHRISTUS Spohn Hospital, Corpus Christi, TX.
Hosp Pract (1995). 2014 Aug;42(3):109-15. doi: 10.3810/hp.2014.08.1123.
The Clinical Assessment Program and Teflaro Utilization Registry (CAPTURE) is a multicenter study, assessing the contemporary use of ceftaroline fosamil in patients with community-acquired bacterial pneumonia (CABP) or acute bacterial skin and skin structure infection. This article discusses the data collected from 528 evaluable patients with CABP, from 39 sites in the United States, between August 2011 and April 2013. The majority of patients (51%) were elderly (aged ≥ 65 years), most of whom were treated in general hospital wards (70%). Approximately one quarter of elderly patients had ≥ 2 comorbidities (26%), the most common of which was structural lung disease (51%). The majority of elderly patients received ceftaroline fosamil as second-line therapy (85%), concurrently with other antibiotics (61%). Similar patterns of ceftaroline fosamil usage were noted in younger patients (aged < 65 years). Fifteen patients died (3%), 10 of whom were elderly. The overall clinical success of ceftaroline fosamil was 81% for elderly patients with CABP and 82% for younger patients. These data suggest that ceftaroline fosamil is a potentially effective treatment option for CABP in the elderly.
临床评估项目与泰福罗使用登记研究（CAPTURE）是一项多中心研究，旨在评估头孢洛林酯在社区获得性细菌性肺炎（CABP）或急性细菌性皮肤及皮肤结构感染患者中的当代使用情况。本文讨论了2011年8月至2013年4月期间从美国39个地点的528例可评估的CABP患者中收集的数据。大多数患者（51%）为老年人（年龄≥65岁），其中大多数在综合医院病房接受治疗（70%）。约四分之一的老年患者有≥2种合并症（26%），最常见的是结构性肺病（51%）。大多数老年患者接受头孢洛林酯作为二线治疗（85%），同时使用其他抗生素（61%）。在年轻患者（年龄<65岁）中也观察到类似的头孢洛林酯使用模式。15例患者死亡（3%），其中10例为老年人。头孢洛林酯在老年CABP患者中的总体临床成功率为81%，在年轻患者中为82%。这些数据表明，头孢洛林酯对老年CABP患者可能是一种有效的治疗选择。
